Draxis subsidiary begins Phase III

Draximage, a subsidiary of Draxis (DRAX; TSE:DAX), began a 130-patient Canadian Phase III trial of its Fibrimage technetium-labeled recombinant polypeptide binding fibrin. The product was developed by...